MA51587A - Conjugués oligomère de sauts d'exons pour la dystrophie musculaire - Google Patents

Conjugués oligomère de sauts d'exons pour la dystrophie musculaire

Info

Publication number
MA51587A
MA51587A MA051587A MA51587A MA51587A MA 51587 A MA51587 A MA 51587A MA 051587 A MA051587 A MA 051587A MA 51587 A MA51587 A MA 51587A MA 51587 A MA51587 A MA 51587A
Authority
MA
Morocco
Prior art keywords
muscle dystrophy
oligomeric conjugates
exon
jumping
exon jumping
Prior art date
Application number
MA051587A
Other languages
English (en)
Other versions
MA51587B1 (fr
Inventor
Gunnar J Hanson
Marco A Passini
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Priority claimed from PCT/US2017/066222 external-priority patent/WO2018118599A1/fr
Publication of MA51587A publication Critical patent/MA51587A/fr
Publication of MA51587B1 publication Critical patent/MA51587B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA51587A 2016-12-19 2017-12-13 Conjugués oligomère de sauts d'exons pour la dystrophie musculaire MA51587B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436182P 2016-12-19 2016-12-19
PCT/US2017/066222 WO2018118599A1 (fr) 2016-12-19 2017-12-13 Conjugués oligomère de sauts d'exons pour la dystrophie musculaire

Publications (2)

Publication Number Publication Date
MA51587A true MA51587A (fr) 2019-10-23
MA51587B1 MA51587B1 (fr) 2022-09-30

Family

ID=65895706

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51587A MA51587B1 (fr) 2016-12-19 2017-12-13 Conjugués oligomère de sauts d'exons pour la dystrophie musculaire

Country Status (2)

Country Link
AR (1) AR110389A1 (fr)
MA (1) MA51587B1 (fr)

Also Published As

Publication number Publication date
MA51587B1 (fr) 2022-09-30
AR110389A1 (es) 2019-03-27

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3347026A4 (fr) Modification génétique de macrophages pour l'immunothérapie
EP3353278A4 (fr) Préparation d'échantillons pour des types d'échantillons compliqués
MA71266A (fr) Procédés d'intervention précoce pour prévenir ou améliorer la toxicité
IL255125A0 (en) Evaluation of cas9 molecule/guide rna molecule complexs
EP3423044A4 (fr) Nanovaccin activant sting pour l'immunothérapie
EP3356612A4 (fr) Détail facilité pour membranes d'imperméabilisation pré-appliquées
MA46652A (fr) Polythérapie pour l'inhibition de c3
EP3334499A4 (fr) Conjugués bioactifs pour l'administration d'oligonucléotides
EP3341485A4 (fr) Production améliorée d'immunoglobulines
MA52801A (fr) Conjugués oligomères à saut d'exon pour dystrophie musculaire
EP3383418A4 (fr) Peptides slc45a2 pour l'immunothérapie
EP3409108A4 (fr) Couvre-lit pour lit d'animaux de compagnie
EP3464636A4 (fr) Extension d'amorce conditionnelle pour la détection de molécule unique
MA45845A (fr) Traitement d'association pour cancers hématologiques
EP3627918C0 (fr) Radiorecherche d'extension de couverture pour ec-gsm
MA46048A (fr) Kit de débutant pour le titrage de l'insuline de base
EP3476478A4 (fr) Composition pour l'élimination de composés soufrés
EP3397360A4 (fr) Ensemble de pédale pour machine d'exercice
FR3034840B3 (fr) Ensemble d'eclairage flexible pour voutes courbees
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3443969A4 (fr) Composition d'amélioration de la fonction cérébrale pour nouveau-nés
EP3633372A4 (fr) Biomarqueur pour la maladie d'alzheimer
EP3344650A4 (fr) Aav-epo pour le traitement d'animaux de compagnie
EP3538087A4 (fr) Réactifs basés sur une oxydo-réduction pour la bioconjugaison d'une méthionine